Last Updated : March 19, 2018
Details
FilesGeneric Name:
Venetoclax
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia
Manufacturer:
AbbVie Corporation
Brand Name:
Venclexta
Project Line:
Reimbursement Review
Project Number:
PC0105-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
10mg, 50 mg & 100mg tablet
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia
Funding Request:
As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-Cell Receptor Inhibitor (BCRi)
Sponsor:
AbbVie Corporation
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : March 19, 2018